MétaCan
Menu
Back to cohort
Record W4317105117 · doi:10.1093/ehjcvp/pvad006

Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial

2023· article· en· W4317105117 on OpenAlexaff
Alessandro Spirito, Adnan Kastrati, Davide Cao, Usman Baber, Samantha Sartori, Dominick J. Angiolillo, Carlo Briguori, David J. Cohen, George Dangas, Dariusz Dudek, Javier Escaned, C. Michael Gibson, Zhongjie Zhang, Upendra Kaul, Ran Kornowski, Vijay Kunadian, Yaling Han, Shamir R. Mehta, Gennaro Sardella, Samin K. Sharma, Richard Shlofmitz, Birgit Vogel, Timothy Collier, Stuart Pocock, Roxana Mehran

Bibliographic record

VenueEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2023
Typearticle
Languageen
FieldMedicine
TopicAntiplatelet Therapy and Cardiovascular Diseases
Canadian institutionsHamilton Health Sciences
FundersJanssen PharmaceuticalsAbbott VascularCytoSorbents EuropeMicroPortIdorsia PharmaceuticalsSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungPharmaMarEisaiSanofiAbiomedAmarin PharmaNovo NordiskAtriCureDaiichi-SankyoMedicines CompanyAstraZenecaAmarin CorporationBristol-Myers SquibbEli Lilly and CompanyCSL BehringDaiichi Sankyo EuropeGilead SciencesAmgenPfizerBoston Scientific CorporationNational Science Foundation
KeywordsTicagrelorMedicineAspirinPercutaneous coronary interventionInternal medicineHazard ratioConventional PCIMyocardial infarctionClinical endpointPlaceboStroke (engine)CardiologyRandomized controlled trialConfidence interval

Abstract

fetched live from OpenAlex

AIM: The aim of this study was to assess the effect of ticagrelor monotherapy among high-risk patients with anaemia undergoing percutaneous coronary intervention (PCI). METHODS AND RESULTS: In the TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention) trial, after 3 months of ticagrelor plus aspirin, high-risk patients were maintained on ticagrelor and randomized to aspirin or placebo for 1 year. Anaemia was defined as haemoglobin <13 g/dL for men and <12 g/dL for women. The primary endpoint was Bleeding Academic Research Consortium (BARC) 2, 3, or 5 bleeding. The key secondary endpoint was a composite of all-cause death, myocardial infarction, or stroke.Out of 6828 patients, 1329 (19.5%) had anaemia and were more likely to have comorbidities, multivessel disease, and to experience bleeding or ischaemic complications than non-anaemic patients. Among anaemic patients, BARC 2, 3, or 5 bleeding occurred less frequently with ticagrelor monotherapy than with ticagrelor plus aspirin [6.4% vs. 10.7%; hazard ratio (HR) 0.60; 95% confidence interval (CI) 0.41-0.88; P = 0.009]; the rate of the key secondary endpoint was similar in the two arms (5.2% vs. 4.8%; HR 1.07; 95% CI 0.66-1.74; P = 0.779). These effects were consistent in patients without anaemia (interaction P values 0.671 and 0.835, respectively). CONCLUSION: In high-risk patients undergoing PCI, ticagrelor monotherapy after 3 months of ticagrelor-based dual antiplatelet therapy was associated with a reduced risk of clinically relevant bleeding without any increase in ischaemic events irrespective of anaemia status (TWILIGHT: NCT02270242).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.065
Threshold uncertainty score0.899

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.003
Bibliometrics0.0010.003
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.279
Teacher spread0.259 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart Journal - Cardiovascular PharmacotherapySame topicAntiplatelet Therapy and Cardiovascular DiseasesFrench-language works237,207